Walgreens Launches New Patient Advisory Board, Advocate Health National Center for Clinical Trials Announced, P95, Julius Clinical Merge

Walgreens Launches New Patient Advisory Board, Advocate Health National Center for Clinical Trials Announced, P95, Julius Clinical Merge

By Clinical Research Staff

November 24, 2025 | Walgreens launches the Walgreens Pharmacy Patient Advisory Board; Advocate Health announces Advocate Health National Center for Clinical Trials, the U.S.’s first, largest, and most inclusive clinical trial network; P95 and Julius Clinical have merged to form a global, full-service clinical research organization; and more.

P95 and Julius Clinical have merged to form a global, full-service clinical research organization with integrated expertise across neuroscience, cardio-renal-metabolic, and infectious diseases and vaccines. The combined organization includes more than 500 professionals in over 25 countries and delivers clinical development and real-world evidence (RWE) programs across five continents. The partnership will utilize Julius Clinical’s global clinical trial expertise and P95’s leadership in epidemiology, infectious diseases, vaccines, and RWE, a combination creating a unified, science-led platform that supports biopharmaceutical and public health partners across the entire development lifecycle. Over the past five years, the organizations have delivered hundreds of neuroscience, cardio-renal-metabolic, and infectious disease programs, including large global clinical trials, epidemiology studies, and global RWE projects. Press release.

BC Platforms launched BC Catalyst, a first-of-its kind AI-native platform that transforms complex genomic and real-world clinical data into actionable insights across the full drug lifecycle. By bridging discovery, development, and real-world evidence, BC Catalyst enables a truly data-driven approach to accelerating therapies and improving patient outcomes through agentic AI-powered queries that help to identify patient cohorts, discover new drug targets, understand genetic variants, and deliver insights on standards of care. Press release.

Advocate Health has formed the Advocate Health National Center for Clinical Trials, a first-of-its-kind, fully integrated solution designed to accelerate discovery by making participation in health care research part of the standard-of-care for its patients across the United States. With 69 hospitals, over 1,000 care locations, and nearly six million patients, the Center will be the nation’s largest and most inclusive clinical trial network. Advocate Health National Center for Clinical Trials is designed to change that paradigm by connecting people to trials in their own communities and by modernizing the clinical trial process through AI-powered tools, centralized data tracking and more. Press release.

Indero completed an internally funded study that introduces a novel approach to evaluating topical new chemical entities (NCE) in early-phase clinical research. This method leverages quantitative gene expression analysis to assess drug efficacy more rapidly and in a cost effective way. The study highlighted advantages of the approach, including: rapid efficacy insights with limited preclinical toxicology requirements and reduced phase 1 costs (3-day study vs. 8–12 weeks); ability to compare multiple NCEs, concentrations, and vehicles within the same patient in short-duration studies; and opportunity to benchmark NCEs against approved topical drugs efficiently. Press release.

Walgreens is launching the Walgreens Pharmacy Patient Advisory Board to ensure patient voices continue to shape how it delivers pharmacy services, especially for those managing chronic and/or complex conditions. The Board will serve as an instrumental tool for understanding patient experiences, ensuring new initiatives and strategies are practical, accessible, and patient-centric. The Board will also supplement and enhance the company’s existing suite of patient engagement platforms, including Walgreens Insights consumer surveys, the Walgreens Clinical Trials Patient Advisory Board and the Walgreens Pharmacy Dean’s Advisory Council. Patient members will serve a one-year term, and advocacy advisors will serve a two-year term, providing ongoing counsel and insights to shape Walgreens’ programs and offerings. Press release.

Neogap Therapeutics has been awarded a $105,000 grant from Vinnova, Sweden’s innovation agency, to initiate a collaborative project with Weill Cornell Medicine. The initiative will explore pathways for conducting future clinical studies in the U.S. The collaboration focuses on advancing Neogap’s novel adoptive T-cell therapy, personalized Tumor Trained Lymphocytes, which uses tumor-draining lymph nodes as a source of tumor-reactive T cells and applies a multi-neoantigen targeting approach. The aim is to make personalized immunotherapy for solid cancers more efficient and broadly accessible. Press release.

Certara launched TFL Studio, the first cloud-native module of its Phoenix Cloud solution. Tables, Figures, and Listings (TFLs) present data on study participants, treatments, and outcomes visually for clear interpretation. They are critical components of regulatory submissions and scientific publications. TFL Studio lets pharmacokinetic and pharmacodynamic scientists create these components with greater speed and collaboration. Press release.

uMotif has deployed MotifAI Assistant, its AI-driven automation, across its product portfolio. The first phase of the MotifAI Assistant initiative focuses on study delivery operations, designed to directly benefit uMotif's customers by enabling faster study builds, improved documentation quality, and even greater consistency across all projects. Press release.

Clinisys released the new version for their Clinisys Laboratory Solution (CLS). These latest innovations, including tailored solutions for Clinical Pathology and Genomics laboratories in North America, empower organizations to accelerate implementation, expand their testing menus, and drive operational excellence. Also included is CLS CARE, an embedded AI-powered chat agent that provides instant, multilingual guidance on functionality, configuration, and usage. Press release.

Kiora has joined Global Genes' RARE-X Vision Consortium, a corporate-nonprofit partnership with a mission to promote and facilitate collaboration among advocacy, research, and industry stakeholders to advance research leading to vision-improving therapies. The Vision Consortium aims to transform the lives of people affected by rare ocular disorders by identifying clinical trial ready populations, ensuring meaningful outcome measures, and accelerating the development of clinical trial programs required to bring new treatments to patients. Press release.

Flatiron Health launched six new hematology Panoramic datasets. Flatiron’s datasets, including five B-cell lymphomas and multiple myeloma, draw from over 505,000 relevant longitudinal patient records in Flatiron’s network. Through application of Flatiron's VALID data quality framework, the datasets maintain the company's data quality standards and will enable life science companies to expand research access to rare patient populations and sub-cohorts of interest. Press release.

Suvoda (recently merged under common ownership with Greenphire) released its unified patient mobile app. The Suvoda app is a single, intuitive experience that will bring visit scheduling, questionnaires, travel information, receipt submission, and reimbursement tracking into one place to reduce the logistical burden for clinical trial participants. The app combines four core product capabilities in one consumer-grade interface so participants can: complete questionnaires and diaries; schedule and reschedule study visits with real-time calendar availability; view travel details and itineraries (coming early 2026); submit receipts and track reimbursement status; and receive automated reminders that help trials stay on track. Press release.